Activists challenge granting of Sovaldi patent in India
Activists have decided to challenge the decision by India's Controller General of Patents, Designs and Trademark to grant US biotech major Gilead Sciences (Nasdaq: GILD) the patent for the blockbuster hepatitis C drug Sovaldi (sofosbuvir) in India, reports The Pharma Letter’s India correspondent.
The company charges a $1,000 per pill (before rebates) in the USA. Though the price of the treatment in India is not expected to be very high due to local competition, with the generic version priced at a comfortable $13.71 per pill in India, domestic drugmakers planning to export the key raw material (API) or others planning to launch the drug in the country are bound to be hit, argue activists who have decided to take the patent office to court.
The USA-based Initiative for Medicines, Access and Knowledge (I-MAK) and the Delhi Network of Positive People (DNP+) have filed an appeal with the Delhi High Court challenging the Delhi Patent Office's decision to accord a patent for sofosbuvir.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze